stockrow
Saturday 7 November 2026
Export ZVRA’s income statement to Excel — free account
Zevra Therapeutics, Inc.
ZVRA Healthcare Biotechnology
Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024.
- Revenue
- +44.9%
- EPS
- +3,333.0%
- Free cash flow
- +106.8%
- Total debt
- +4.07%
Quarter to September 2026, against a year earlier
11.55
1.02
+9.69%
Follow ZVRA
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
8.55 | 15.09 | 4.55 | 6.54 |
+8 more quarters Free account |
P/S ratio |
4.41 | 6.23 | 4.45 | 4.65 | |
P/FCF ratio |
7.48 | 10.34 | 43.60 | 0.00 | |
P/Operating CF |
64.86 | 49.81 | 88.63 | 89.85 | |
P/B ratio |
2.73 | 3.90 | 2.65 | 3.20 | |
Price to Tangible BV |
2.85 | 4.09 | 2.79 | 3.45 | |
EV/Sales |
3.76 | 5.34 | 3.63 | 3.80 | |
EV/EBITDA |
6.23 | 9.01 | 8.43 | 0.00 | |
EV/Operating CF |
14.35 | 21.75 | 34.73 | (252.94) | |
EV/FCF |
6.38 | 8.86 | 35.51 | (203.63) | |
Quick Ratio |
5.21 | 5.02 | 4.74 | 5.46 | |
Current Ratio |
5.46 | 5.17 | 4.89 | 5.68 | |
Net Debt/EBITDA |
(16.33) | (13.39) | (3.87) | (14.64) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 21.75% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.40 | |
Asset Turnover |
0.51 | 0.49 | 0.54 | 0.46 | |
Operating CF/Net income |
0.55 | 2.03 | 0.17 | 0.47 | |
Capex/Depreciation |
(0.60) | (20.52) | (171.65) | 0.22 | |
Interest Coverage |
— | — | 30.48 | 4.78 | |
Research and Development Expense of Revenue |
13.08% | 11.31% | 12.13% | 7.68% | |
Selling, General and Administrative Expense of Revenue |
50.67% | 41.75% | 57.38% | 59.65% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.04 | 0.04 | |
Share Based Compensation of Revenue |
7.08% | 7.49% | 8.57% | 12.55% | |
Graham Net Nets |
0.23 | 0.20 | 0.29 | 0.19 | |
Graham Number |
10.78 | 8.87 | 12.75 | 9.28 | |
Earnings Yield |
11.70% | 6.62% | 22.00% | 15.29% | |
Free Cash Flow Yield |
13.36% | 9.67% | 2.29% | (0.40%) | |
Revenue per Share |
0.64 | 0.67 | 0.62 | 0.62 | |
Operating CF per Share |
0.17 | 0.29 | 0.11 | 0.10 | |
Capex per Share |
0.00 | 0.08 | 0.75 | 0.00 | |
Free Cash Flow per Share |
0.17 | 0.37 | 0.86 | 0.10 | |
Cash per Share |
3.29 | 3.75 | 3.43 | 3.45 | |
Shareholders Equity per Share |
4.02 | 3.68 | 3.52 | 2.80 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.02 | 3.68 | 3.52 | 2.80 | |
Free Cash Flow |
9.81 | 21.77 | 50.08 | 5.41 | |
Working Capital |
184.47 | 202.67 | 182.94 | 183.73 | |
Capital Expenditures |
(0.24) | 4.74 | 43.94 | (0.11) | |
Net Current Asset Value |
151.19 | 166.24 | 157.19 | 92.93 | |
EV/EBIT |
6.19 | 8.82 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | (0.12) | (1.21) | 0.00 | |
Price to Operating Income |
7.26 | 10.30 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
18.39 | 20.38 | 17.36 | 16.88 | |
Average Payables |
12.37 | 14.90 | 14.75 | 18.53 | |
Average Inventory |
2.22 | 1.78 | 2.43 | 1.86 | |
Average Assets |
291.85 | 279.49 | 225.64 | 231.43 | |
Average Common Equity |
186.04 | 167.44 | 123.41 | 97.16 |
Columns are period end dates · fundamentals updated 5 Nov 2026